52509-29-2

Upstream product

• 148-53-8 3-methoxy-2-hydroxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 2011-06-5 2-benzyloxy-3-methoxybenzaldehyde 
• 52508-44-8 2-benzyloxy-3-hydroxymethyl-1-methoxybenzene 

Downstream Products

• 628330-08-5 (2-benzyloxy-3-methoxyphenyl)acetonitrile 
• 39595-88-5 2-(2-(benzyloxy)-3-methoxyphenyl)acetic acid 

Relevant academic research and scientific papers

Method for preparing and splitting phenylalanine ester compound

The invention provides a method for preparing and splitting a phenylalanine ester compound. The phenylalanine ester compound, namely high-yield products, is prepared by performing an alkylation reaction on an alkylating agent and a Schiff base compound an

Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs

Receptor antagonists may be effective antipsychotic drugs that do not induce motor side effects caused by ingestion of classical drugs such as haloperidol. We obtained evidence that 1-(2-dipropylaminoethyl)-4-methoxy- 6H-dibenzo[b,d]pyran hydrochloride 2a had selective affinity for σ receptor over dopamine D2 receptor. This compound was designed to eliminate two bonds of apomorphine 1 to produce structural flexibility for the nitrogen atom and to bridge two benzene rings with a -CH2O- bond to maintain the planar structure. In light of the evidence, N,Y-dipropyl-2-(4-methoxy-3- benzyloxylphenyl)ethylamine hydrochloride 10b was designed. Since compound 10b had eliminated a biphenyl bond of 6H-dibenzo[b,d]pyran derivative 2a, it might be more released from the rigid structure of apomorphine 1 than compound 2a. The chemical modification of compound 10b led to the discovery that N,N-dipropyl-2-[4-methoxy-3-(2-phenylethoxyl)phenyl]ethylamine hydrochloride 10g (NE- 100), the best compound among arylalkoxyphenylalkylamine derivatives 3, had a high and selective affinity for σ receptor and had a potent activity in an animal model when the drug was given orally. We report here the design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine derivatives 3.

Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties

This invention relates to novel substituted 1,2,3,4-tetrahydroisoquinolines which are useful in the treatment of vascular restenosis, various disorders of the central nervous system, in the regulation of female reproductive functions, in cognitive enhance